|
23 Nov 2021 |
Arrowhead Pharmaceuticals Enters Exclusive License Agreement with GSK for ARO-HSD
|
|
22 Nov 2021 |
Baidu Enters Into License Agreement With Sanofi to Enable Next-Generation mRNA Therapeutics and Vaccines
|
|
22 Nov 2021 |
Zenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from Xencor
|
|
22 Nov 2021 |
Vifor Pharma to spearhead development of vascular calcification field, through acquisition of Sanifit Therapeutics and Inositec AG
|
|
19 Nov 2021 |
Gilead Exercises Options to Three Arcus Biosciences Clinical-Stage Programs and Adds Research Collaboration
|
|
18 Nov 2021 |
Novo Nordisk to acquire Dicerna Pharmaceuticals including the RNAi research technology platform
|
|
18 Nov 2021 |
AVILAR THERAPEUTICS LAUNCHES WITH $60 MILLION SEED FINANCING TO PIONEER EXTRACELLULAR PROTEIN DEGRADATION Company founded and financed by RA Capital Management with
|
|
16 Nov 2021 |
SOTIO Expands its Antibody-Drug Conjugate Pipeline with Exclusive Collaboration and License Agreement with LegoChem Biosciences
|
|
16 Nov 2021 |
ACELYRIN, INC. Closes $250 Million Series B Financing and Announces Licensing of Izokibep, a Late-Stage IL-17A Inhibitor to Treat Inflammatory Diseases
|
|
16 Nov 2021 |
Twist Bioscience Launches Revelar Biotherapeutics to Develop and Commercialize Novel COVID-19 and Other Antibody Therapeutics for Difficult to Treat Diseases
|
|
16 Nov 2021 |
Recludix Pharma Launches with $60 Million Series A to Support Innovative Platform to Discover and Develop Novel SH2 Domain-Targeted Therapies for Cancer and Inflammatory Diseases; Appoints Dr. Nancy Whiting as CEO
|
|
12 Nov 2021 |
Organon to Acquire Forendo Pharma
|
|
10 Nov 2021 |
Xencor Reports Third Quarter 2021 Financial Results and Announces Encouraging Preliminary Data from Ongoing Phase 1 Study of Potency-reduced IL15-Fc Cytokine, XmAb306
|
|
09 Nov 2021 |
EdiGene Enters Research Collaboration with the University of Wisconsin-Madison on In Vivo RNA Editing Therapies
|
|
04 Nov 2021 |
Dalriada Drug Discovery Celebrates Client Dunad Therapeutics Billion Dollar Collaboration with Novartis
|
|
04 Nov 2021 |
Alpha Tau Announces Enrollment of First Patient in Combination Trial of Alpha DaRT™ and Pembrolizumab (Keytruda®)
|
|
02 Nov 2021 |
Dunad Therapeutics enters Strategic Collaboration with Novartis to Develop Next-generation Oral Targeted Protein Degrader Therapies
|
|
01 Nov 2021 |
Venatorx Pharmaceuticals Announces Collaboration with Roche to Develop New Class of Antibiotics targeting WHO Critical Priority Pathogen
|
|
01 Nov 2021 |
Imugene and Eureka Therapeutics Announce Strategic Collaboration to Accelerate Advancement of Oncolytic Virus and T-Cell Therapy in Solid Tumours
|
|
01 Nov 2021 |
Synthekine Establishes Collaboration with Merck to Develop Therapeutic Candidates Using its Proprietary Surrogate Cytokine Agonist Platform
|
|
28 Oct 2021 |
MaxCyte Signs Strategic Platform License with Nkarta, Inc. to Advance Natural Killer Cell Therapy Programs
|
|
28 Oct 2021 |
Pan Cancer T Extends Seed Financing Round with Additional Funding from Existing Shareholders and New Investor Thuja Capital
|
|
28 Oct 2021 |
Agomab Therapeutics to Acquire Origo Biopharma
|
|
27 Oct 2021 |
Takeda to Acquire GammaDelta Therapeutics to Accelerate Development of Allogeneic γδT Cell Therapies Addressing Solid Tumors
|
|
27 Oct 2021 |
Mozart Therapeutics Launches with $55 Million Series A Financing to Develop Disease Modifying Therapeutics for Autoimmune and Inflammatory Diseases
|
